Mohammad Ali hassanzadeh

Mohammad Ali hassanzadeh


Research Focus & Metrics

Academic Career Length

2Years (2025-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
20 May 2025 in Cancer Epidemiology
Verified
Journal Article
Closed access
HMHabibeh Mashayekhi-Sardoo
Habibeh Mashayekhi-Sardoo
ZGZohreh-Al-Sadat Ghoreshi
Zohreh-Al-Sadat Ghoreshi
HAHedyeh Askarpour
Hedyeh Askarpour
NAnasir arefinia
nasir arefinia
MHMohammad Ali hassanzadeh
Mohammad Ali hassanzadeh

23 June 2026 in International Journal of Surgery Case Reports
Verified
Journal Article
Open access
HAHedyeh Askarpour
Hedyeh Askarpour
MHMohammad Ali hassanzadeh
Mohammad Ali hassanzadeh
Was not provided for this article.

13 May 2025 in Virus Research
Verified
Journal Article
Open access
NAnasir arefinia
nasir arefinia
HAHedyeh Askarpour
Hedyeh Askarpour
ZGZohreh-Al-Sadat Ghoreshi
Zohreh-Al-Sadat Ghoreshi
HMHabibeh Mashayekhi-Sardoo
Habibeh Mashayekhi-Sardoo
MHMohammad Ali hassanzadeh
Mohammad Ali hassanzadeh
Sjögren syndrome (SS) is one of the lesser-known autoimmune diseases, with its mechanisms and pathogenesis not yet fully understood. However, recent studies indicate that infectious diseases, such as Hepatitis C virus (HCV) infection, may serve as risk factors for the development of SS. Accordingly, this study aimed to estimate the global co-occurrence rate of chronic HCV infection and SS. In this systematic review and meta-analysis, a comprehensive search for relevant studies was conducted in PubMed, Scopus, ISI Web of Science, and Google Scholar databases up to June 2024. Data from eligible studies were meticulously extracted and statistically analyzed using Comprehensive Meta-Analysis Software. The pooled prevalence of co-occurrence of HCV and SS was calculated using incidence rates with 95 % confidence intervals (CIs), and the association of chronic HCV infection with the development of SS was assessed via odds ratios (ORs) with 95 % CIs. Analysis of the articles retrieved from the databases showed 24 studies were considered eligible. The pooled estimate for the co-occurrence of HCV and SS was approximately 16.6 % (95 % CI: 8.8-28.9). Moreover, the results indicated that chronic HCV infection significantly increased the risk of developing SS (OR: 2.76; 95 % CI: 1.35-5.63). This study's findings revealed that HCV infection may play a role in the pathogenesis of and susceptibility to SS. Therefore, chronic HCV infection may trigger the onset of SS. However, further studies are required to confirm these results.

1 November 2025 in International Journal of Surgery Case Reports
Verified
Journal Article
Open access
HZHamidreza Zivarifar
Hamidreza Zivarifar
ARAmirbahram Rahimzadeh
Amirbahram Rahimzadeh
FAForough Ahrari
Forough Ahrari
MHMohammad Ali hassanzadeh
Mohammad Ali hassanzadeh

18 June 2026 in Genes & Nutrition
Verified
Journal Article
Open access
MBMohammad Vesal Bideshki
Mohammad Vesal Bideshki
MNMaedeh Nojoumi
Maedeh Nojoumi
MBMehrdad Behzadi
Mehrdad Behzadi
NANasir Arefinia
Nasir Arefinia
HAHedyeh Askarpour
Hedyeh Askarpour
MHMohammad Ali hassanzadeh
Mohammad Ali hassanzadeh
Synbiotics (combined probiotics + prebiotics) may ameliorate oxidative stress via gut microbiota-mediated mechanisms. However, previous syntheses were limited in biomarker scope and contaminated by retracted or compromised trials. This updated meta-analysis of randomized controlled trials (RCTs) aims to quantify the effects of synbiotic supplementation on a comprehensive panel of oxidative stress biomarkers in adults and to appraise the certainty of evidence. Following PRISMA guidance and a registered protocol, RCTs in adults comparing oral synbiotic supplementation (≥ 3 weeks) versus placebo were eligible. Primary outcomes were changes in malondialdehyde (MDA), total oxidant status (TOS), oxidative stress index (OSI), nitric oxide (NO), total antioxidant capacity (TAC), superoxide dismutase (SOD), glutathione peroxidase (GPx), and reduced glutathione (GSH). Data were pooled using a random-effect model (standardized mean differences, SMD; 95% CI). Heterogeneity (I²), sensitivity, subgroup and publication-bias analyses were performed. Evidence certainty was rated with GRADE; studies formally retracted or with serious concerns were excluded. Eighteen RCTs were included. Synbiotic supplementation significantly reduced MDA (SMD: -0.87; 95% CI: -1.37, -0.37), TOS (SMD: -0.55; 95% CI: -1.03, -0.08) and OSI (SMD: -0.46; 95% CI: -0.78, -0.15). Antioxidant markers, including TAC (SMD: 0.25; 95% CI: 0.06, 0.43), SOD (SMD: 0.57; 95% CI: 0.13, 1.00), GSH (SMD: 0.70; 95% CI: 0.11, 1.28), and GPx (SMD: 1.40; 95% CI: 0.39, 2.40), were increased. GRADE ratings ranged from very low (MDA, GPx) to moderate (OSI). Synbiotic supplementation may improve certain oxidative stress biomarkers, including TAC, GSH, and MDA. However, findings for NO and OSI should be interpreted with caution due to the limited number of available studies and the low to very low certainty of evidence for some outcomes according to GRADE criteria. Further high-quality, large-scale RCTs are warranted to confirm these effects. https://www.crd.york.ac.uk/PROSPERO/view/CRD420251103060.